Novel benzoxazine-based aglycones block glucose uptake in vivo by inhibiting glycosidases by Bharathkumar, H. et al.
Novel Benzoxazine-Based Aglycones Block Glucose
Uptake In Vivo by Inhibiting Glycosidases
Hanumantharayappa Bharathkumar1., Mahalingam S. Sundaram2., Swamy Jagadish3,
Shardul Paricharak4,5, Mahadevappa Hemshekhar2, Daniel Mason4, Kempaiah Kemparaju2,
Kesturu S. Girish2, Basappa1*, Andreas Bender4*, Kanchugarakoppal S. Rangappa3*
1 Laboratory of Chemical Biology, Department of Chemistry, Bangalore University, Bangalore, India, 2Department of Studies in Biochemistry, University of Mysore,
Mysore, India, 3Department of Chemistry, University of Mysore, Manasagangotri, Mysore, India, 4Unilever Centre for Molecular Science Informatics, Department of
Chemistry, University of Cambridge, Cambridge, United Kingdom, 5Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research, Leiden University, Leiden,
The Netherlands
Abstract
Glycoside hydrolases catalyze the selective hydrolysis of glycosidic bonds in oligosaccharides, polysaccharides, and their
conjugates. b-glucosidases occur in all domains of living organisms and constitute a major group among glycoside
hydrolases. On the other hand, the benzoxazinoids occur in living systems and act as stable b-glucosides, such as 2-(2,4-
dihydroxy-7-methoxy-2H-1,4-benzoxazin-3(4H)-one)-b-D-gluco-pyranose, which hydrolyse to an aglycone DIMBOA. Here,
we synthesized the library of novel 1,3-benzoxazine scaffold based aglycones by using 2-aminobenzyl alcohols and
aldehydes from one-pot reaction in a chloroacetic acid catalytic system via aerobic oxidative synthesis. Among the
synthesized benzoxazines, 4-(7-chloro-2,4-dihydro-1H-benzo[d][1,3]oxazin-2-yl)phenol (compound 7) exhibit significant
inhibition towards glucosidase compared to acarbose, with a IC50 value of 11.5 mM. Based upon results generated by in silico
target prediction algorithms (Naı¨ve Bayesian classifier), these aglycones potentially target the additional sodium/glucose
cotransporter 1 (where a log likelihood score of 2.70 was observed). Furthermore, the in vitro glucosidase activity was
correlated with the in silico docking results, with a high docking score for the aglycones towards the substrate binding site
of glycosidase. Evidently, the in vitro and in vivo experiments clearly suggest an anti-hyperglycemic effect via glucose
uptake inhibition by 4-(7-chloro-2,4-dihydro-1H-benzo[d][1,3]oxazin-2-yl)phenol in the starved rat model. These synthetic
aglycones could constitute a novel pharmacological approach for the treatment, or re-enforcement of existing treatments,
of type 2 diabetes and associated secondary complications.
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Introduction
Diabetes mellitus, particularly its subtype 2 (T2-DM), is
considered to be a major and increasing threat to human health
and accounts for an estimated more than 300 million cases of
diabetes worldwide [1,2]. Diabetes is associated with a significant
number of co morbidities, such as cardiovascular disorders, stroke,
diabetic retinopathy and kidney dysfunction, and long-term
complications may even lead to limb amputations, among other
consequences [2].
In addition to injectable insulin and analogs thereof, four
distinct classes of oral hypoglycemic agents are currently used for
the treatment of T2-DM. In addition to metformin as an oral drug
used for the early control of T2-DM, there are a number of
second- and third-line pharmacological agents available, such as
sulfonylureas, thiazolidinediones, incretin-based remedies, and a-
glucosidase inhibitors. Given the increased perception that
handling the early stages of diabetes is of crucial importance,
several recent studies and approaches are focusing on agents that
can delay or inhibit glucose absorption. Delaying glucose
absorption, such as by blocking glycoside hydrolases (particularly
a-glucosidases), allows extended time for b-cells to increase insulin
secretion, and thereby reduce circulatory glucose levels [3,4].
a-glucosidases are membrane-bound enzymes that catalyze the
selective hydrolysis of glycosidic bonds in oligosaccharides,
polysaccharides, and their conjugates to release glucose and the
respective monosaccharides. Although they occur throughout
living organisms, most of them are located in the brush border of
the small intestine to facilitate glucose uptake [4,5]. Thus, the use
of a-glucosidase inhibitors (AGIs) for the treatment of T2-DM
delays the release of glucose and halts glucose absorption, thereby
lowering the postprandial blood glucose level and improving pre-
diabetic conditions. The currently most prominent AGIs are
acarbose (Glucobay), a natural compound from an Actinoplanes
strain, and the N-hydroxyethyl analogue of 1-deoxynojirimycin,
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miglitol [4,6]. However, these compounds have been reported to
cause severe gastrointestinal complications.
Numerous efforts have hence been made to further develop
AGIs in order to improve treatment of pre-diabetic states [7,8].
Glycosides, the natural substrates for the glycoside hydrolases
which are composed of an aglycone and a glycan moiety, have
recently attracted particular attention in this field. Stable b-
glucosides such as 2-(2,4-dihydroxy-7-methoxy-2H-1,4-benzoxa-
zin-3(4H)-one)-b-D-gluco-pyranoside and desmethoxy derivatives
including 6,7-dimethoxy-benzoxazolin-2(3H)-one, 4-hydroxy-2H-
1,4-benzoxazin-3(4H)-one, and 4-acetylbenzoxazolin-2(3H)-one,
are found in living plants [9]. These glucosides are biologically
inactive, but enzymatically converted to active aglycones such as
DIMBOA (2,4-dihydroxy-7-methoxy-2H-1,4-benzoxazin-3(4H)-
one and the desmethoxy derivative DIBOA, by b-glucosidases
[10]. These products have diverse effects, that include anti-auxin,
anti-inflammatory, and powerful antibiotic activities. These
aglycones are further degraded spontaneously to the correspond-
ing benzoxazolinones, MBOA (6-methoxy-benzoxazolin-2(3H)-
one) and the desmethoxy derivative BOA. Degradation is faster if
the benzene ring and amide linkage bears electron donating or
hydroxyl groups [11], and these chemical variations are what we
explored in more detail in the current work. In addition to this,
our aim was to remove the relatively labile N-hydroxy amide
moiety via replacement by a suitable ring system, masking the
glycosylation site of glycoside (Fig. 1). These efforts have the goal
of increasing efficacy of the compounds in vivo, in order to lower
blood sugar levels by inhibiting glucosidase.
Materials and Methods
Chemicals/ Reagents
Rat intestinal acetone powder was purchased from Sigma
Aldrich, St. Louis (USA), Acarbose was purchased from Glucobay
Bayer AG (Germany). Porcine pancreatic a-Amylase and Yeast a-
Glucosidase were purchased from SRL, Mumbai (India). Glucose
oxidase (GOD POD) kit was purchased from Piramal HealthCare
Ltd, Mumbai (India). All other chemicals used were of analytical
grade and purchased from Sigma Aldrich, St. Louis (USA) and
SRL, Mumbai (India). All IR spectra were obtained in KBr disc on
a Shimadzu FT-IR 157 Spectrometer. 1H and 13C NMR spectra
were recorded on a Bruker WH-200 (400 MZ) spectrometer in
CDCl3 or DMSO-d6 as solvent, using TMS as an internal
standard and chemical shifts are expressed as ppm. Mass spectra
were determined on a Shimadzu LC-MS. The elemental analyses
were carried out using an Elemental Vario Cube CHNS rapid
Analyzer. The progress of the reaction was monitored by TLC
pre-coated silica gel G plates.
Experimental animals
Adult Wistar rats weighing 150–180 g were collected from the
University Central Animal Facility and housed under a controlled
environment. All animal experiments were approved by the
Institutional Animal Ethical Committee (Order No : MGZ/2620/
2011-12 Dated 31-01-2012; UOM/IAEC/18/2011), Department
of Studies in Zoology, University of Mysore, Mysore and were in
accordance with the guidelines of the Committee for the Purpose
of Control and Supervision of Experiments on Animals
(CPCSEA).
Synthesis and characterization of 1,3-benzoxazine
derivatives
This work is based on the previous synthesis of an oxazine
derivative which was able to mimic the pyranoside structure of
glycans functionally [12]. In continuation of the glycobiological
aspects, the one-pot syntheses of a novel 1,3-benzoxazine scaffold
was carried out using 2-aminobenzyl alcohols and different
aldehydes in chloroacetic acid via aerobic oxidative synthesis
(Fig. 2).
General Procedure for the Synthesis of
benzoxazines. To a 50 mL round bottom flask, amino benzyl
alcohol (1.0 equiv), aldehyde (1.0 equiv), chloroacetic acid (1.0
equiv) and methanol (10 mL) were added. The reaction mixture
was then stirred at room temperature for 16 h. Water was added
to the reaction mixture, and extracted with ethyl acetate. The
organic layer was dried by using anhydrous sodium sulphate, and
then concentrated in vacuum to afford compound benzoxazine as
a crystalline solid. The compounds were then purified by column
chromatography and characterized via IR, 1H NMR, 13C NMR,
mass spectrometry and Elemental Analysis.
Synthesis of 4-(2,4-dihydro-1H-benzo[d][1,3]oxazin-2-
yl)phenol 1. The product 1 was obtained from 2-amino benzyl
alcohol (1.23 g,10 mmol), 4-hydroxy benzaldehyde (1.22 g,
10 mmol) and chloroacetic acid 0.94 g (10 mmol). This com-
pound was obtained as brownish solid in 83% yield. IR nmax
(KBR): 3277,2924, 1514, 1220 cm21, 1H NMR (400 MHz,
CDCl3 d in ppm) d 4.13(1H, s, NH) 4.80-4.90 (2H, s, CH2) 5.02
(1H, s, O-H) 5.28 (1H, s,-CH) 6.70-6.72(1H, d, Aromatic -CH)
6.9–7.2 (5H, m, Ar-CH) 8.06 (1H, s, Ar-CH); 13C NMR 70.05,
97.95, 114.64, 120.47, 126.08, 126.13, 129.13, 129.79, 130.22,
Figure 1. Scheme for the proposed strategy for the synthesis of 1,3-benzoxazine derivatives.
doi:10.1371/journal.pone.0102759.g001
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138.07, 147.90, 155.51. MASS; m/z found for C14H13NO2 228.2
([M+1]+).
Synthesis of 2-(1H-indol-3-yl)-2,4-dihydro-1H-
benzo[d][1,3]oxazine 2. The product 2 was obtained from
2-amino benzyl alcohol (1.23 g, 10 mmol), indole-3-carbaldehyde
(1.45g, 10 mmol) and chloroacetic acid 0.94g (10 mmol). This
compound was obtained as black color solid in 82% yield. IR
nmax (KBR): 3252, 2898, 1493, 1244 cm21, 1H NMR
(400 MHz, CDCl3 d in ppm) 4.25 (1H,s,NH), 4.70 (2H,s,- CH2-
) 5.12 (1H,s,-CH-), 7.07-7.50(5H,m, Ar-H), 8.01–8.64(4H,m, Ar-
H), 11.80 (1H,s,Indole-NH); Anal. Calcd.for C16H14N2O: C,
76.78; H, 5.64; N, 11.19; found C, 76.54; H, 5.51; N, 11.53 %.
MASS; m/z found for C16H14ClN2O 251.3 ([M+1]+).
Synthesis of 2-(2-methyl-1H-indol-3-yl)-2,4-dihydro-1H-
benzo[d][1,3]oxazine 3. The product 3 was obtained from
2-amino benzyl alcohol (1.23 g, 10 mmol), 2-methyl indole-3-
carbaldehyde (1.59 g, 10 mmol) and chloroacetic acid 0.94g
(10 mmol). This compound was obtained as black colour solid in
87% yield. IR nmax (KBR): 3212, 2788, 1462, 1238 cm21, 1H
NMR (400 MHz, CDCl3 d in ppm) 2.11(3H,s, -CH3-), 4.13
(1H,s,-N-H-), 4.83 (2H,s,-CH2-) 5.19 (1H,s-CH-); 7.26(3H,m,-Ar-
CH-) 8.06–8.22(5H,m,Ar-CH), 10.12(1H,s,N-H INDOLE) Anal.
Calcd.for C17H16N2O; C, 77.25; H, 6.10; N, 10.60; found C,
77.14; H, 6.11; N, 10.43%; MASS; m/z found for C17H16N2O
264.4 ([M+1]+).
Synthesis of 2-(1-(4-(2-cyanophenyl)benzyl-1H-indol-3-
yl),2,4-dihydro-1H-benzo(d)(1,3) oxazine 4. The product 4
was obtained from 2-amino benzyl alcohol (1.23 g, 10 mmol), 2-
(1-(4-(2-cyanophenyl )1-benzyl-1H-indole-3-carbaldehyde (3.36 g,
10 mmol) and chloroacetic acid 0.94 g (10 mmol). This com-
pound was obtained as brown colour solid in 86% yield. IR nmax
(KBR): 3182, 2918, 1473, 1294 cm21, 1H NMR (400 MHz,
CDCl3 d in ppm) 4.09 (1H,s, -NH), 4.7 (2H,s,-CH2), 5.4 (3H,s,-
CH), 5.4 (3H,s,-CH2) 7.26–8.35 (17H,m,-Ar-CH-) Anal. Calcd.for
C30H23N3O; C, 81.61; H, 5.25; N, 9.52; found C, 81.14; H, 5.11;
N, 9.43%. MASS; m/z found for C30H23N3O 442.4 ([M+1]+).
Synthesis of 3-(2,4-dihydro-1H-benzo[d][1,3]oxazin-2-yl)-
4H-chromen-4-one 5. The product 5 was obtained from 2-
amino benzyl alcohol (1.23 g, 10 mmol), 4-oxo-4H-chromene-3-
carbaldehyde (3.21 g, 10 mmol) and chloroacetic acid 0.94 g
(10 mmol). This compound was obtained as brownish solid in 89%
yield. IR nmax (KBR): 3302, 2918, 1463, 1215 cm21, 1H NMR
(400 MHz, CDCl3 d in ppm) 4.11 (1H,s,NH), 4.80 (1H,s,-CH-)
5.32 (2H,s,-CH2-), 7.07–8.32(7H,m, Ar-H) 8.55(H,s, Ar-O-CH);
13C NMR 70.1, 85.5, 110.6, 115.2,116.1, 119.6,122.0,127.6,
127,8, 129.2, 132.6, 133.6, 142.2, 149.1,155.6, 179.2; Anal. Calcd.
for C17H13NO3: C, 73.11; H, 4.69; N, 5.02; found C, 73.54; H,
4.51; N, 5.23 %; MASS; m/z found for C17H13NO3 278.3
([M-1]+).
Synthesis of 2-(2-butyl-4-chloro-1H-imidazol-5-yl)-2,4-
dihydro-1H-benzo[d][1,3]oxazine 6. The product 6 was
obtained from 2-amino benzyl alcohol (1.23 g, 10 mmol), 2-
butyl-4-chloro-1H-imidazole-5-carbaldehyde (1.86 g, 10 mmol)
and chloroacetic acid 0.94 g (10 mmol). This compound was
obtained as black colour solid in 86% yield. IR nmax (KBR): 3225,
2892, 1433, 1214 cm21 1H NMR (400 MHz, CDCl3 d in ppm)
0.90 (3H,t,CH3), 1.30 (2H,m,- CH2-) 1.60 (2H,m,-CH2-), 2.60
(2H,t,CH2), 4.30 (1H,s,- NH-) 4.60 (2H,s,-CH2-), 5.60 (1H,s,- CH-
) 6.60–7.60 (4H,m, Ar-H), 8.2 (1H,s, imidazole N-H) Anal.
Calcd.for C15H18ClN3O: C, 61.75; H, 6.22; N, 14.40; found C,
61.54; H, 6.51; N, 14.53 %. MASS; m/z found for C15H18ClN3O
292.2 ([M+1]+).
Synthesis of 4-(7-chloro-2,4-dihydro-1H-benzo[d][1,3]
oxazin-2-yl)phenol 7. The product 7 was obtained from 2-
amino-4-chloro benzyl alcohol (1.57 g, 10 mmol), 4-hydroxy
benzaldehyde (1.22 g, 10 mmol) and chloroacetic acid 0.94 g
(10 mmol). This compound was obtained as brownish solid in 87%
yield. IR nmax (KBR): 3258, 2897, 1487, 1269 cm21 1H NMR
(400 MHz, CDCl3 d in ppm) d 4.13(1H,s,NH) 4.80-4.90
(2H,s,CH2) 5.02 (1H,s,O-H) 5.28 (1H,s,-CH) 6.70-6.72(2H,d,
Aromatic -CH) 6.9–7.2 (4H,m,Ar-CH) 8.06 (1H,s,Ar-CH). 13C
NMR 68.97, 94.73, 110.80, 115.66, 119.08, 129.97, 130.40,
133.39, 134.24, 139.12, 149.38, 159.12. Anal. Calcd.for
C14H12ClNO2; C, 64.25; H, 4.62; N, 5.35; found C, 64.14; H,
4.21; N, 5.53%. MASS; m/z found for C14H12ClNO2 262.2 ([M+
1]+).
Synthesis of 7-chloro-2-(1H-indol-3-yl)-2,4-dihydro-1H-
benzo[d][1,3]oxazine 8. The product 8 was obtained from
2-amino-5-chloro benzyl alcohol (1.57 g,10 mmol), indole-3-
carbaldehyde (1.45 g, 10 mmol) and chloroacetic acid 0.94 g
(10 mmol). This compound was obtained as brownish solid in 85%
yield. IR nmax (KBR): 3213, 2978, 1448, 1236 cm21, 1H NMR
(400 MHz, CDCl3 d in ppm) 4.25 (1H,s,NH), 4.70 (2H,s,- CH2-)
5.12 (1H,s,-CH-), 7.07-7.50(5H,m, Ar-H), 8.01–8.64(3H,m, Ar-
H), 11.80 (1H,s,Indole-NH); Anal. Calcd. for C16H13ClN2O: C,
67.49; H, 4.60; N, 9.84; found C, 66.54; H, 4.51; N, 9.53%;
MASS; m/z found for C16H13ClN2O 285.8 ([M+1]+).
Synthesis of 6-chloro-2-(2-phenyl-1H-indol-3-yl)-2,4-
dihydro-1H-benzo[d][1,3]oxazine 9. The product 9 was
obtained from 2-amino-5-chloro benzyl alcohol (1.57 g, 10 mmol),
2-phenyl indole-3-carbaldehyde (2.21 g, 10 mmol) and chloroa-
cetic acid 0.94 g (10 mmol). This compound was obtained as
colourless solid in 89% yield. IR nmax (KBR): 3232, 2843, 1452,
1243 cm21, 1H NMR (400 MHz, CDCl3 d in ppm) 2.31(2H,s,
Figure 2. General procedure for the synthesis of novel benzoxazines.
doi:10.1371/journal.pone.0102759.g002
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-CH2-), 2.39 (3H,s,CH3), 5.11 (1H,s,-C-H), 4.2 (1H,s,-N-H-) 6.26–
8.41 (12H,m,Ar-CH-); 10.00 (1H,s,N-H) Anal. Calcd.for
C22H17N2OCl; C, 73.23; H, 4.72; N, 7.76; found C, 73.34; H,
4.31; N, 7.43%; MASS; m/z found for C22H17ClN2O 361.5
([M+1]+).
Synthesis of 3-(6-chloro-2,4-dihydro-1H-benzo[d][1,3]
oxazin-2-yl)-4H-chromen-4-one 10. The product 10 was
obtained from 2-amino -5-chloro benzyl alcohol (1.57 g,10 mmol),
4-oxo-4H-chromene-3-carbaldehyde (1.74 g, 10 mmol) and chlor-
oacetic acid 0.94 g (10 mmol). This compound was obtained as
brownish solid in 83% yield. IR nmax (KBR): 3219, 2797, 1488,
1285 cm21 1H NMR (400 MHz, CDCl3 d in ppm) 4.11
(1H,s,NH), 4.80 (1H,s,-CH-) 5.32 (2H,s,-CH2-), 7.77–8.55(7H,m,
Ar-H); Anal. Calcd.for C17H12ClNO3: C, 65.08; H, 3.86; N, 4.46;
found C, 66.54; H, 3.51; N, 4.23%; MASS; m/z found for
C17H12ClNO3 314.0 ([M+1]+).
Synthesis of 6-methyl-2-(2-methyl-1H-indol-3-yl)-2,4-
dihydro-1H-benzo[d][1,3]oxazine 11. The product 11 was
obtained from 2-amino-5-methyl benzyl alcohol (1.37 g,10 mmol),
2-methyl indole-3-carbaldehyde (1.59 g, 10 mmol) and chloroa-
cetic acid 0.94 g (10 mmol). This compound was obtained as light
yellow colour solid in 80% yield. IR nmax (KBR): 3219, 2818,
1513, 1284 cm21, 1H NMR (400 MHz, CDCl3 d in ppm)
2.40(3H,s, -CH3-), 2.5 (3H,s,-CH3), 4.6 (2H,s,-CH2), 5.25 (1H,s,-
CH) 6.67–7.32 (7H,m,-Ar-CH-) 10.15(1H,s,N-H), Anal. Calcd.for
C18H18N2O; C, 77.67; H, 6.52; N, 10.06; O, 5.75; found C,
77.14; H, 6.11; N, 10.43%. MASS; m/z found for C18H18N2O
278.2, 280.2 ([M+1]+).
Synthesis of 6-methyl-2-(2-phenyl-1H-indol-3-yl)-2,4-
dihydro-1H-benzo[d][1,3]oxazine 12. The product 12 was
obtained from 2-amino-5-methyl benzyl alcohol (1.37 g,
10 mmol), 2-phenyl indole-3-carbaldehyde (2.21 g, 10 mmol)
and chlor acetic acid 0.94 g (10 mmol). This compound was
obtained as colourless solid in 86% yield. IR nmax (KBR): 3210,
2817, 1433, 1224 cm21, 1H NMR (400 MHz, CDCl3 d in ppm)
2.31(2H, s, -CH2-), 2.39 (3H, s, CH3), 5.11 (1H, s, -C-H), 4.2 (1H,
s, -N-H-) 6.26–8.41 (12H, m, Ar-CH-); 10.00 (1H, s, N-H) Anal.
Calcd. for C23H20N2O; C, 81.15; H, 5.92; N, 8.23; found C,
81.34; H, 5.71; N, 8.43%; MASS; m/z found for C23H20N2O
341.2 ( [M+1]+).
Synthesis of 3-(6-methyl-2,4-dihydro-1H-benzo[d][1,3]
oxazin-2-yl)-4H-chromen-4-one 13. The product 13 was
obtained from 2-amino-5-methyl benzyl alcohol (1.37 g,
10 mmol), 4-oxo-4H-chromene-3-carbaldehyde (1.74 g, 10 mmol)
and chloro acetic acid 0.94 g (10 mmol). This compound was
obtained as yellow color solid in 88% yield. IR nmax (KBR): 3241,
2828, 1413, 1224 cm21, 1H NMR (400 MHz, CDCl3 d in ppm)
2.20(3H,s, -CH3-), 4.11-4.13 (1H,s,-N-H), 4.11-4.13 (1H, s, -C-H),
4.79 (1H, s, -CH2-) 5.26 (1H, s, -CH2-); 6.6–8.3 (7H, m, -Ar-CH-)
8.5(1H, s, O-CH), Anal. Calcd. for C18H15NO3; C, 73.71; H,
5.15; N, 4.78; found C, 73.14; H, 5.11; N, 4.43%; Mass; m/z
found for C18H15NO3 294.1 ([M+1]+).
Inhibitory activity against a-Amylase
The a-amylase inhibition assay was performed according to a
previous report [13]. Porcine pancreatic a-amylase (3 units/mL)
was dissolved in 0.1 M phosphate buffered saline, pH 6.9. The
various concentrations of 1,3-benzoxazine derivatives (0–100 mM)
were pre-incubated with enzyme independently for 10 min at
37uC. The reaction was initiated by adding substrate solution
(0.1% starch) to the incubation medium. After 10 min incubation,
the reaction was stopped by adding 250 mL dinitrosalicylic (DNS)
reagent (1% 3, 5-dinitrosalicylic acid, 0.2% phenol, 0.05%
Na2SO3 and 1% NaOH in aqueous solution) to the reaction
mixture. The reaction was terminated by keeping the reaction
mixture in boiling water bath for 10 min. Thereafter, 250 mL of
40% potassium sodium tartarate solution was added to the
mixtures to stabilize the colour. After cooling to room temperature
in a cold water bath, the absorbance was recorded at 540 nm
using a Varioskan multimode plate reader (Thermo Scientifics,
USA). Acrabose was used as positive control. The percentage of
inhibition was calculated using Abs Contol – Abs Sample6100/
Abs Control. Where Abs Control was the absorbance without
sample, Abs sample was the absorbance of enzyme with
compound. Concentration-response assays were used to determine
the potency (IC50) of 1,3-benzoxazine derivatives based on the
logistic analysis of the concentration-response curve using Micro-
soft Excel.
Inhibitory activity against a-Glucosidase
The a-glucosidase inhibitory activities of synthesized com-
pounds were evaluated using the method developed by Tsujii et al.
[14]. Briefly, a-glucosidase was dissolved in phosphate buffer
(50 mM, pH 6.9) and pre-treated with various concentrations of
1,3-benzoxazine derivatives (0–100 mM) independently for 10 min
at 37uC. The reaction was initiated by the addition of 50 mL of
5 mM p-nitrophenyl- a -D-glucopyranoside solution in phosphate
buffer (50 mM, pH 6.9). The enzyme reaction was carried out at
37uC for 30 min. The reaction was terminated by the addition of
Na2CO3 (1 M). The enzymatic activity of a-glucosidase was
quantified by measuring the absorption at 405 nm using a
Varioskan multimode plate reader (Thermo Scientifics, USA).
The inhibitory effect of compounds was defined as inhibitory
activity (%) = (Abs Control – Abs Compound treated)/Abs
Control 6100. Concentration-response assays were used to
determine the potency (IC50) of 1,3-benzoxazine derivatives based
on the logistic analysis of the concentration-response curve using
Microsoft Excel.
Intestinal a-glucosidase inhibitory assay
Intestinal a-glucosidase activity was determined by measuring
the amount of glucose hydrolyzed from maltose or sucrose [15].
Briefly, rat intestinal acetone powder was homogenized in 0.9%
saline and the suspension was centrifuged at 10,000 g for 30 min
at 4uC and the supernatant obtained was used as enzyme source.
The enzyme solution was pre-incubated with various concentra-
tions of compound 7 (5–25 mM) or acarbose (5 mM) or combined
[5 mM acarbose with increasing concentrations of compound 7
(1–10 mM)] in 100 mM phosphate buffer pH 6.9 at 37uC for
10 min and the reaction was started by adding maltose (37 mM)
or sucrose (56 mM) and incubated at 37uC for 30 min (for
maltase) and 60 min (for sucrase). After the respective incubation
period, reaction was terminated by keeping the samples in boiling
water bath for 10 min. The concentration of glucose released from
the reaction mixtures was determined by using Glucose oxidase
(GOD POD) kit according to the manufacturer’s protocol. Results
were expressed as percentage inhibition of intestinal maltase/
sucrase activity.
Oral maltose and sucrose tolerance test
The experimental animals were randomly divided into 11
groups each consisting of 5 rats. Following overnight fasting,
animals were assigned to the following groups and treated with the
respective compounds through oral gavage: Group - I Saline
control (0.9% saline); Group - II Maltose control (3 g/kg); Group -
III Sucrose control (3 g/kg); Group -IV Acarbose (3 mg/kg) +
Maltose; Group - V Acarbose (3 mg/kg) + Sucrose; Group - VI
Compound 7 (50 mg/kg) + Maltose; Group - VII Compound 7
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(100 mg/kg) + Maltose; Group - VIII Compound 7 (50 mg/kg) +
Sucrose; Group - IX Compound 7 (100 mg/kg) + Sucrose; Group
- X Acarbose (3 mg/kg) + Compound 7 (50 mg/kg) + Maltose;
Group –XI Acarbose (3 mg/kg) + Compound 7 (50 mg/kg) +
Sucrose. 5 minutes following compound 7 or Acarbose adminis-
tration either maltose (3 g/kg) or sucrose (3 g/kg) solution were
administered to the respective groups. Blood was collected from
the tail vein to the tubes containing anticoagulant (2.5% trisodium
citrate and 1.37% citric acid in the ratio 1:5; anti-coagulant: blood)
at time point 0 (just before sucrose/maltose administration), and
subsequently at 30, 60, 90, 120 and 180 min after substrate
(sucrose/maltose) administration. Plasma was separated by cen-
trifuging the samples at 2000 rpm for 10 min and stored at220uC
until analysis. Plasma glucose concentration was determined by
using the Glucose oxidase (GOD POD) kit according to the
manufacturer’s protocol.
Glucose uptake study
Porcine diaphragm was purchased from a slaughter house, and
cleaned using ice cold 0.9% saline several times to remove blood
stains. This diaphragm was used for glucose uptake and inhibition
by compound 7. Diaphragm (100 mg) was suspended in a 24 well
culture plate containing 500 mL saline. In order to initiate the
reaction, 5 mM glucose was added to each well. To enhance the
glucose uptake by the diaphragm, 1 unit of insulin was used in
each well, and the volume was made up to 1 ml with saline. For
inhibition studies, compound 7 at a concentration of 50 & 100 mM
was used. From each well 100 mL of the assay mixture was
aspirated at different time intervals (0, 5, 10, 20, 30 and 60 min).
From this, glucose concentration was measured using Glucose
oxidase (GOD POD) kit according to the manufacturer’s protocol.
Molecular docking studies
The software Insight II/Discovery Studio 2.5 from Accelrys was
used for docking and visualization of the results as described
earlier [16]. The crystal structure of amylase was retrieved
(PDBID: 3TOP). Before performing the Ligand fit protocol of
Discovery Studio, the protein was cleaned, and the size and spatial
orientation of the active site was identified. All energy calculations
were performed using the CHARMM force field. Each energy-
minimized final docking position of the ligands was evaluated
using the interaction score function in the Ligand Fit module of
Discovery Studio as reported previously [17].
Chem-informatics analysis
Utilizing the available amount of bioactivity data, we also
rationalized the modes-of-action for the experimentally tested
benzoxazines using in silico target prediction approaches. To this
end, the Parzen-Rosenblatt Window classifier was employed with
the smoothing parameter set to 0.9, using approximately 190,000
bioactive compounds covering 477 human protein targets as the
training dataset. For details on the method, dataset and validation
see reference 15.
Statistical analysis
Results are expressed as mean values 6 SEM of three
independent experiments. Data were compared by analysis of
variance (ANOVA) followed by the Tukey ‘‘honestly significantly
different’’ (HSD) post hoc analysis. Significance was accepted at
p,0.05 (*), p,0.01 (**) and p,0.001 (***).
Results and Discussion
This work is based upon the previous synthesis of an oxazine
derivative which was able to mimic the pyranoside structure of
glycans functionally [12]. In continuation of the glycobiological
aspects, the one-pot syntheses of novel 1,3-benzoxazine scaffold
was carried out using 2-aminobenzyl alcohols and different
aldehydes in chloroacetic acid via aerobic oxidative synthesis
(Fig. 2). The above design principles led to the synthesis of 13
compounds (Table 1) whose a-glucosidase inhibitory activity was
validated both in vivo as well as in vitro, and supported by
computational approaches as described below. The synthesized
aglycones inhibited both a-glucosidase and a-amylase activity,
with overall relatively similar IC50 values between 11 mM and
60 mM (Table 1). Among the tested derivatives, compound 7{(4-
(7-chloro-2,4-dihydro-1H-benzo[d][1,3]oxazin-2-yl)phenol} ex-
hibiting strong inhibition of both glucosidases, with an IC50 values
of 11 mM and 11.5 mM for a-amylase and a-glucosidase respec-
tively. The addition of phenolic and halogen substituents to the
1,3-benzoxazine ring was found to increase the inhibitory potency
(compound 7), whilst the incorporation of a flavone moiety
decreases the inhibitory potency (compounds 5, 10, and 13). 1,3-
benzoxazines bearing an electron withdrawing chlorine substituent
were found to be more potent against a-glucosidase (compound 7),
whereas the electron donating methyl group was not particularly
favoured (compound 11). Introduction of an imidazole ring
(compound 6), to give 1,3-benzoxazine, resulted in an enhanced
inhibition (IC50 = 16 mM), while a chromene moiety decreased the
activity (compound 13).
To study the efficacy of the potent a-glucosidase inhibitor,
compound 7 was tested for in vivo maltose and sucrose tolerance
test on overnight fasted experimental rats by taking acarbose as
positive control as well as glucose uptake by porcine diaphragm by
using insulin as enhancer. It can be seen that acarbose (3mg/kg)
significantly reduced the plasma glucose concentration at 30, 60,
90 min time intervals in starved rats treated with maltose as
substrate compared to maltose control (Fig. 3A). In sucrose fed
rats differences are less pronounced and were only significant at 60
and 90 min time points (Fig. 3B). At a concentration of 50 mg/kg
body weight, compound 7 inhibited glucose uptake in rats fed with
maltose, which was similar to acarbose treatment at 30 and
60 min. However, compound 7 significantly reduced plasma
glucose concentration at the 90 min time point compared to
acarbose, indicating a different Pharmacokinetic/Pharmacody-
namic (PK/PD) profile of compound 7 on between these
substrates. Furthermore, compound 7 significantly reduced the
plasma glucose concentration throughout all time points (0–
180 min) compared to the acarbose treated group when sucrose
was used as a substrate (Fig. 3B). At a concentration of 100 mg/
kg bodyweight, compound 7 was significantly more effective than
the acarbose standard at all time points. In order to establish
possible synergistic effects between compound 7 and acarbose,
plasma glucose levels were measured in starved rats fed
individually with maltose and sucrose at different time points up
to 180 minutes. In both cases, synergistic activity of compound 7
(50 mg/kg bodyweight) and acarbose (3 mg/kg bodyweight)
prevented substrate utilization, and the plasma glucose concen-
tration remained unchanged when compared to the saline treated
group. The inhibitory efficacy of compound 7 on rat intestinal
glucosidases (maltase and sucrase) was also evaluated. The
compound showed both maltase and sucrase inhibitory activities
in a dose-dependent manner (Fig. 4A and 4B). Acarbose
inhibited both the intestinal glucosidases activity with an IC50
value of 3.5 mM (maltase) and 4 mM (sucrase), while compound 7
Novel Benzoxazines that Targets Glycosidases
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was found to be two-fold selective for maltase (IC50 = 10 mM) over
sucrase (IC50 = 20 mM). Furthermore, acarbose and compound 7
synergistically inhibited intestinal maltase more efficiently com-
pared to intestinal sucrase (Fig. 4C and 4D).
Further, porcine diaphragm was used in order to understand
the effect of compound 7 on insulin mediated glucose uptake via
GLUT4. The glucose transporter isoforms GLUT4 and GLUT1
are highly expressed in muscle cells, with GLUT4 being more
abundant in an intracellular compartment from which it is quickly
translocated to the plasma membrane as a response to insulin
challenge. Both insulin-dependent and non-insulin-dependent
diabetes were shown to reduce glucose utilization in muscle either
due to a defective expression or dysregulation in GLUT4
translocation [3,18]. In the present study, glucose uptake was
found to be normal in the control group treated with no insulin.
However as expected, significant increased glucose uptake was
observed in diaphragm treated with insulin (1 U) compared to
control. We found that compound 7 at a dose of 50 and 100 mM
significantly blocked the glucose uptake both in control and insulin
treated diaphragm in a dose-dependent manner (Fig. 5).
In addition to in vivo and in vitro experimental validation of the
intended target of a-glucosidase shown above, in silico target
prediction [19,20] was performed with the full set of 13
synthesized compounds, in order to obtain a more comprehensive
impression of the bioactivity profile of the synthesized 1,3-
benzoxazine derivatives. It was found that only compound 7, the
most active in the series, is predicted to target the sodium/glucose
co transporters 1 and 2, which may contribute to the in vivo
efficacy of this compound. However, no experimental validation of
this additional target has been performed.
In order to hypothesize a binding mode, molecular docking has
been performed between compound 7 and maltase-glucoamylase
(Fig. 6).The crystal structure of MGAM-C (Human maltase-
glucoamylase C terminal domain) in complex with its inhibitor
Acarbose (PDB ID: 3TOP) was used as a model to determine the
molecular interaction between enzyme and the synthesized 1,3-
Table 1. Physical characteristics and inhibitory activities (a-glucosidase and a-amylase) of novel 1,3-benzoxazines.
Sl No. Benzoxazines Yield
Melting
Point
a-Glucosidase
IC50 (mM)
a-Amylase
IC50 (mM)
1 4-(2,4-dihydro-1H-benzo[d][1,3]oxazin-2-yl)phenol 83% 160-162uC 17.160.1 20.460.2
2 2-(1H-indol-3-yl)-2,4-dihydro-1H-benzo[d][1,3]oxazine 82% 65-67uC 32.060.2 59.261.0
3 2-(2-methyl-1H-indol-3-yl)-2,4-dihydro-1H-benzo[d][1,3]oxazine 87% 70-72uC 21.660.1 10.660.3
4 2-(1-(4-(2-cyanophenyl)benzyl-1H-indol-3-yl),2,4-dihydro-1H-benzo(d)(1,3) oxazine 86% 122-124uC NS NS
5 3-(2,4-dihydro-1H-benzo[d][1,3]oxazin-2-yl)-4H-chromen-4-one 89% 142-144uC NS 23.360.5
6 2-(2-butyl-4-chloro-1H-imidazol-5-yl)-2,4-dihydro-1H-benzo[d][1,3]oxazine 86% 80-82uC 16.761.0 18.560.1
7 4-(7-chloro-2,4-dihydro-1H-benzo[d][1,3]oxazin-2-yl)phenol 87% 139-141uC 11.560.1 11.060.3
8 7-chloro-2-(1H-indol-3-yl)-2,4-dihydro-1H-benzo[d][1,3]oxazine 85% 125-127uC 27.761.0 26.460.5
9 6-chloro-2-(2-phenyl-1H-indol-3-yl)-2,4-dihydro-1H-benzo[d][1,3]oxazine 89% 220-222uC 27.860.2 22.260.1
10 3-(6-chloro-2,4-dihydro-1H-benzo[d][1,3]oxazin-2-yl)-4H-chromen-4-one 83% 141-143uC 31.960.8 NS
11 6-methyl-2-(2-methyl-1H-indol-3-yl)-2,4-dihydro-1H-benzo[d][1,3]oxazine 80 % 102-104uC 23.860.1 NS
12 6-methyl-2-(2-phenyl-1H-indol-3-yl)-2,4-dihydro-1H-benzo[d][1,3]oxazine 86% 220-222uC 20.560.5 17.660.3
13 3-(6-methyl-2,4-dihydro-1H-benzo[d][1,3]oxazin-2-yl)-4H-chromen-4-one 88% 202-204uC NS 51.060.3
Acarbose 4.360.04 4.460.02
NS-not significant.
doi:10.1371/journal.pone.0102759.t001
Figure 3. In vivo effect of compound 7 {4-(7-chloro-2,4-dihydro-1H-benzo[d][1,3]oxazin-2-yl)phenol} and acarbose on plasma
glucose concentration by oral (A) maltose and (B) sucrose tolerance test. Values are presented as mean 6 SEM (n= 5). *p,0.05, **p,0.01,
***p,0.001 significant compared to respective maltose/sucrose alone treated groups.
doi:10.1371/journal.pone.0102759.g003
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Figure 4. In vitro effect of compound 7 and its synergistic effect with acarbose on rat intestinal maltase and sucrase activities.
Percentage inhibition of compound 7 on intestinal (A) maltase and (B) sucrose. Percentage inhibition of intestinal maltase (C) and sucrase (D) induced
by the compound 7 in presence of acarbose. Percentage inhibition is presented as mean 6 SEM of three independent experiments. *p,0.05, **p,
0.01, ***p,0.001 significant compared to acarbose.
doi:10.1371/journal.pone.0102759.g004
Figure 5. Effect of compound 7 on glucose transport across porcine diaphragm in the presence and absence of insulin. Values are
presented as presented as mean 6 SEM of three independent experiments. ***p,0.001 significant compared to insulin alone treated diapharagm.
doi:10.1371/journal.pone.0102759.g005
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benzoxazine derivatives [21]. In MGAM, both the N- and C-
terminal domains (MGAM-N and MGAM-C) carry out the same
catalytic function with different substrate specificities. The
MGAM-C hydrolyzes linear a-1,4-linked oligosaccharide sub-
strates and plays a pivotal role in the production of glucose in the
human lumen and considered as an efficient drug target for T2-
DM. Since, there is no information regarding the co-crystal
structure of murine glucosidase and acarbose, we have used the
co-crystal structure of MGAM-C and acarbose for docking studies.
The synthesized 1,3-benzoxazine derivatives have relatively
similar IC50 values, Dock Score (column ‘DS’) in particular seems
to show higher scores for the more active compounds (7, 1 and 6)
as opposed to less active compounds (2, 8, 9 and 10) (Table 2).
Structurally, the most active compound 7, binds deep in the
MGAM catalytic domain (Fig. 7), in which the chloro-
benzoxazine ring stacks into the hydrophobic cluster of
Tyr1251, Trp1355, Trp1369, Tyr1427, Phe1559, and Phe1560,
along with the phenolic ring stacked to Tyr1251, His1584,
Trp1418, and Trp1523. The terminal hydroxyl group of the
phenolic component of compound 7 shows hydrogen bonding
with Asp1279 and Ile1280, which are also involved in hydrogen
bonding with the terminal hydroxyl group of Acarbose in the co-
crystal. In addition, the exposed oxygen atom in the benzoxazine
ring of compound 7 appears to show ionic interaction with
Asp1526 and Arg1510, which is also crucial in the Acarbose-
MGAM co-crystal. These results clearly suggest that both acarbose
and compound 7 shares similar binding pattern towards MGAM-
C.
Finally, we applied a metabolite prediction software, namely
MetaPrint2D-React [22], to bioactive compound 7 and found the
most likely metabolic site to be a glucuronidation site with a
(significant) normalised occurrence ratio of less than 0.33 and but
greater than 0.15. Hence, this study for the first time demonstrated
the design, synthesis, and characterization of novel 1,3-benzox-
azine aglycones and their validation in vitro and in vivo.
Compound 7 significantly inhibited rat intestinal glucosidases,
namely maltase and sucrase, in a dose-dependent fashion and led
to decreased blood sugar levels in starved rat model. In addition to
Figure 6. Interaction map of MGAM-C domain co-crystallized with acarbose. The labelled key amino acids are represented as a stick model
with the carbon atom as green, and other atoms in their parent colours. The binding of acarbose, whose carbon atom is coloured in pink and other
atoms with their parent colour. The hydrogen bonding is represented as dark dotted line.
doi:10.1371/journal.pone.0102759.g006
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this, compound 7 acts synergistically with Acarbose in lowering the
blood sugar levels to that of the saline control alone.
Summary
This study demonstrated the novel synthesis of benzoxazine
glycones and their effective inhibition towards glucosidases. The
newly synthesized 1,3-benzoxazine derivatives showed better IC50
values for both a-glucosidase and a-amylase, ranging from 11–
60 mM, and are found to be effective when compared to natural
substrate aglycones, such as BOA and derivatives that deteriorate
fatter in aqueous solution. The in silico molecular docking studies
revealed that benzoxazines bind to the catalytic domain of
MGAM-C, correlating with a high DS for the most active
compound 7. The docking score of compound 7 and binding poses
were found to be similar with the anti-diabetic drug acarbose.
Furthermore, studies of in silico target prediction algorithms
showed that compound 7 potentially targets the sodium-glucose
cotransporter 1. Both in vitro and in vivo experimental results
suggested an anti-hyperglycemic effect of compound 7, which
significantly inhibits glucose uptake in starved rat model by
blocking intestinal maltase and sucrase. Evidently, compound 7
was determined to possess the glucuronidation site, which
potentially converts it into a stable glycoside in vivo. The
aglycones synthesized in this study could hence constitute a novel
pharmacological starting point for the treatment or alleviation of
T2-DM and its secondary complications. However, further studies
elucidating interaction between compound 7 and specific glucose
transporters would be highly exciting.
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